TVTX
Travere Therapeutics Inc.
$44.29
-$0.14(-0.32%)
46
Overall
20
Value
63
Tech
57
Quality
Market Cap
$3.93B
Volume
1.81M
52W Range
$13.88 - $48.61
Target Price
$53.21
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $133.6M | $154.9M | $164.2M | $175.3M | $198.3M | $227.5M | $109.5M | $145.2M | $233.2M | $490.7M | ||
| Total Revenue | $133.6M | $154.9M | $164.2M | $175.3M | $198.3M | $131.8M | $109.5M | $145.2M | $233.2M | $490.7M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-4.6M | $-3.6M | $-5.5M | $5.2M | $6.1M | $3.8M | $4.4M | $11.4M | $7.7M | $10.3M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $129.0M | $151.3M | $147.1M | $170.1M | $192.2M | $128.0M | $105.0M | $133.8M | $225.4M | $480.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-191.8M | $-208.7M | $227.4M | $269.9M | $364.7M | $360.2M | $424.9M | $510.5M | $481.6M | $543.2M | ||
| Research & Development | $70.8M | $78.2M | $123.8M | $141.0M | $228.9M | $210.3M | $227.3M | $245.0M | $217.5M | $206.0M | ||
| Research Expense | $70.8M | $78.2M | $123.8M | $141.0M | $228.9M | $210.3M | $227.3M | $245.0M | $217.5M | $206.0M | ||
| Selling, General & Administrative | $91.9M | $101.3M | $103.7M | $129.0M | $135.8M | $149.9M | $197.5M | $265.5M | $264.1M | $337.2M | ||
| Selling & Marketing Expenses | $91.9M | $101.3M | $103.7M | -- | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | -- | -- | -- | $129.0M | $135.8M | $149.9M | $197.5M | $265.5M | $264.1M | $337.2M | ||
| Salaries & Wages | $-29.1M | $-26.9M | $-19.8M | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-100.0K | $-500.0K | $-600.0K | $700.0K | $2.1M | $1.7M | $2.1M | $2.2M | $1.8M | -- | ||
| Depreciation & Amortization | $-100.0K | $-500.0K | $-600.0K | $700.0K | $2.1M | $1.7M | -- | -- | -- | -- | ||
| Amortization | $-16.0M | $-18.7M | $-18.0M | $19.7M | $22.4M | $24.9M | $18.6M | $36.3M | $41.7M | -- | ||
| Other Operating Expenses | $-191.8M | $-208.7M | $-244.3M | $-235.0K | $-1.2M | $-2.3M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-33.7M | $-28.2M | $-80.3M | $-137.4M | $-176.2M | $-161.8M | $-319.8M | $-388.1M | $-323.8M | $-62.8M | ||
| EBITDA | $-40.5M | $-34.2M | $-69.6M | $-98.1M | $-145.2M | $-184.5M | $-297.8M | $-324.5M | $-264.0M | $23.9M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $-800.0K | $4.4M | $9.8M | $18.8M | $19.1M | $19.7M | $11.0M | $11.3M | $11.2M | $10.7M | ||
| Intinc | $-759.0K | $4.1M | $5.5M | $10.1M | $-14.0M | $-18.1M | $-4.7M | $21.8M | $17.8M | $12.7M | ||
| Net Non-Operating Interest Income/Expense | $-759.0K | $-4.4M | $-4.3M | $-8.7M | $-14.0M | $-18.1M | $4.7M | $10.4M | $6.6M | $2.0M | ||
| Gain on Sale of Securities | -- | $100.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $17.0M | $22.8M | $17.5M | $15.3M | $-1.4M | $-231.0K | $-6.6M | $-1.6M | $3.3M | $-11.6M | ||
| Other Special Charges | $1.4M | $-3.4M | $-17.5M | $-314.0K | $1.4M | $231.0K | $-6.6M | $1.6M | $-3.3M | $11.6M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $893.0K | $3.6M | $-242.0K | -- | -- | -- | -- | $11.4M | $2.4M | -- | ||
| Special Income Charges | $-6.1M | $-6.2M | $242.0K | $-25.5M | -- | -- | -- | $-11.4M | $-2.4M | -- | ||
| Impairment of Capital Assets | -- | -- | -- | $25.5M | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-58.4M | $-54.0M | $-92.1M | $-127.6M | $-169.7M | $-197.2M | $-320.1M | $-364.8M | $-309.3M | $-38.5M | ||
| Pre-Tax Income | $-57.6M | $-58.4M | $-101.9M | $-146.4M | $-188.8M | $-179.7M | $-331.2M | $-376.1M | $-320.5M | $-49.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-9.7M | $1.4M | $811.0K | $-21.0K | $-19.4M | $409.0K | $313.0K | $223.0K | $120.0K | $988.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-47.8M | $-60.0M | $-102.7M | $-146.4M | $-169.4M | $-180.1M | $-278.5M | $-111.4M | $-321.5M | $-25.5M | ||
| Net Income (Continuing Operations) | $-47.8M | $-60.0M | $-102.7M | $-146.4M | $-169.4M | $-180.1M | $-331.5M | $-376.3M | $-320.6M | $-50.3M | ||
| Net Income (Discontinued Operations) | $-47.8M | $-60.0M | $-102.7M | $-146.4M | $-169.4M | $-180.1M | $-278.5M | $-111.4M | $-321.5M | $-25.5M | ||
| Net Income (Common Stockholders) | $-47.8M | $-60.0M | $-102.7M | $-152.3M | $-169.4M | $-180.1M | $-278.5M | $-111.4M | $-321.5M | $-25.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-48.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-196.4M | $-212.3M | $221.9M | $275.1M | $370.8M | $367.0M | $429.3M | $522.0M | $489.4M | $553.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $37.0M | $38.8M | $40.4M | $42.3M | $47.5M | $59.8M | $63.8M | $74.3M | $78.9M | $89.2M | ||
| Average Shares Outstanding (Diluted) | $38.3M | $38.8M | $40.4M | $42.3M | -- | $59.8M | $63.8M | $74.3M | $78.9M | $89.2M | ||
| Shares Outstanding | $38.1M | $39.7M | $41.4M | $43.1M | $60.2M | $63.2M | $64.7M | $76.1M | $88.7M | $92.2M | ||
| Basic EPS | $-1.29 | $-1.54 | $-2.54 | $-3.46 | $-3.56 | $-3.01 | $-4.37 | $-1.5 | $-4.08 | $-0.29 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-3.46 | $-3.56 | $-3.01 | $-4.37 | $-5.07 | $-4.07 | $-0.57 | ||
| Diluted EPS | $-1.29 | $-1.54 | $-2.54 | $-3.46 | $-3.56 | $-3.01 | $-4.37 | $-1.5 | $-4.08 | $-0.29 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-3.01 | $-4.37 | $-5.07 | $-4.07 | $-0.57 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | $3.57 | $-0.01 | $0.28 | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | $3.57 | $-0.01 | $0.28 | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | $-7.5M | -- | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | $-7.5M | -- | -- | $53.0M | $264.9M | $-915.0K | $24.7M | ||
| Net Operating Interest Income Expense | -- | $3.2M | $5.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | $5.2M | $2.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | -- | -- | -- | $264.9M | $-915.0K | $24.7M | ||
| Other Gand A | -- | -- | -- | $129.0M | $135.8M | $149.9M | $197.5M | $265.5M | $264.1M | $337.2M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $15.0M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $91.9M | $101.3M | $103.7M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $893.0K | $3.6M | $-242.0K | -- | -- | -- | -- | $11.4M | $2.4M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TVTX | $44.29 | -0.3% | 1.81M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Travere Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW